There are two possibilities regarding the action of HCQS in COVID-19: first, individuals who have received hydroxychloroquine will have a compromised immune system due to which HCQS becomes inactive as a prophylactic or therapeutic medication; second, there can be a lowering of CD4 cell count and an elevation of CD8 cell count after administration of hydroxychloroquine. The gene discussed is CD8A; the disease is COVID-19.